Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

Experts discuss the patient case of Janet, a 58-year-old with her 2 positive metastatic breast cancer, and after 14 months on ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Scientists at King’s College London have developed an innovative IgE antibody therapy that activates the immune system to ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer.

Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

REVEAL GENOMICS ®, a pioneering Barcelona-based biotech company dedicated to advancing precision oncology, is proud to announce the publication of a groundbreaking study demonstrating the clinical ...

Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

Less than two months ago, 52-year-old Oklahoma State Representative Melissa Provenzano underwent a mastectomy for stage one ...